Leaflet SEHCAT 370 KBQ capsules


Indicated for: diagnostic imaging

Route of administration: oral

Substance: selenium (75Se) tauroselcholic acid (contrast agent)

ATC: V09DX01 (Various | Hepatic and reticulo endothelial system | Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals)

Selenium (75Se) tauroselcholic acid is a radioactive compound used in imaging studies to evaluate liver and biliary function. It is administered intravenously and tracked using imaging techniques to assess bile flow and liver function.

The medication is used under the supervision of a nuclear medicine specialist, and the dose is adjusted based on the patient's needs. It is important for patients to inform the doctor of any pre-existing conditions or allergies.

Patients should be aware of potential side effects, such as allergic reactions or discomfort at the injection site. It is important to inform the doctor of any unusual symptoms.

Common side effects include discomfort at the injection site and mild allergic reactions. In rare cases, severe reactions such as hypersensitivity may occur. Patients should be informed of these risks before administration.

General data about SEHCAT 370 KBQ

  • Substance: selenium (75Se) tauroselcholic acid
  • Date of last drug list: 01-09-2023
  • Commercial code: W69711001
  • Concentration: 370kBq
  • Pharmaceutical form: capsules
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: GE HEALTHCARE BUCHLER GMBH & CO. KG - GERMANIA
  • Holder: GE HEALTHCARE BUCHLER GMBH & CO. KG - GERMANIA
  • Number: 15075/2023/01
  • Shelf life: 18 saptamâni-after packing for marketing;12 saptamâni-data de referinta înscrisa pe eticheta